{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T12:29:41Z","timestamp":1794486581038,"version":"4.9.1"},"reference-count":133,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brain Research Bulletin"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.brainresbull.2019.01.004","type":"journal-article","created":{"date-parts":[[2019,1,8]],"date-time":"2019-01-08T20:40:22Z","timestamp":1546980022000},"page":"171-184","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":112,"special_numbering":"C","title":["Recent therapeutic strategies targeting beta amyloid and tauopathies in Alzheimer's disease"],"prefix":"10.1016","volume":"146","author":[{"given":"Yamini","family":"Madav","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0124-1741","authenticated-orcid":false,"given":"Sarika","family":"Wairkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bala","family":"Prabhakar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.brainresbull.2019.01.004_bib0005","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nsmb.1799","article-title":"Structural conversion of neurotoxic amyloid-beta(1-42) oligomers to fibrils","volume":"17","author":"Ahmed","year":"2010","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0010","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2174\/156720508785132307","article-title":"Mechanism of tau-induced neurodegeneration in Alzheimer disease and related tauopathies","volume":"5","author":"Alonso","year":"2008","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0015","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3389\/fncel.2018.00338","article-title":"Hyperphosphorylation of tau associates with changes in its function beyond microtubule stability","volume":"12","author":"Alonso","year":"2018","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0020","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.brainresbull.2016.08.018","article-title":"Tau and tauopathies","volume":"126","author":"Arendt","year":"2016","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0025","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/j.1471-4159.2005.03576.x","article-title":"The novel beta-secretase inhibitor KMI-429 reduces amyloid beta peptide production in amyloid precursor protein transgenic and wild-type mice","volume":"96","author":"Asai","year":"2006","journal-title":"J. Neurochem."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0030","doi-asserted-by":"crossref","first-page":"9115","DOI":"10.1523\/JNEUROSCI.2361-07.2007","article-title":"Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements","volume":"27","author":"Asuni","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0035","doi-asserted-by":"crossref","first-page":"7910","DOI":"10.1523\/JNEUROSCI.16-24-07910.1996","article-title":"Matrix metalloproteinase-9 (MMP-9) is synthesized in neurons of the human hippocampus and is capable of degrading the amyloid-beta peptide (1-40)","volume":"16","author":"Backstrom","year":"1996","journal-title":"J. Neurosci."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0040","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1124\/jpet.114.219352","article-title":"Complex disposition of methylthioninium redox forms determines efficacy in tau aggregation inhibitor therapy for Alzheimer\u2019s disease","volume":"352","author":"Baddeley","year":"2015","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0045","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/nrn2194","article-title":"Tau-mediated neurodegeneration in Alzheimer\u2019s disease and related disorders","volume":"8","author":"Ballatore","year":"2007","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0050","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0196-9781(02)00261-9","article-title":"Passage of amyloid beta protein antibody across the blood-brain barrier in a mouse model of Alzheimer\u2019s disease","volume":"23","author":"Banks","year":"2002","journal-title":"Peptides"},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0055","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.neubiorev.2018.11.020","article-title":"Apolipoprotein E and affective symptoms in mild cognitive impairment and Alzheimer\u2019s disease dementia: a systematic review and meta-analysis","volume":"96","author":"Banning","year":"2018","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0060","doi-asserted-by":"crossref","first-page":"32","DOI":"10.2174\/1567205012666141218140953","article-title":"Amyloid-beta protein clearance and degradation (ABCD) pathways and their role in Alzheimer\u2019s disease","volume":"12","author":"Baranello","year":"2015","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0065","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/00002093-200210000-00001","article-title":"Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida brain Bank","volume":"16","author":"Barker","year":"2002","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0070","doi-asserted-by":"crossref","first-page":"7137","DOI":"10.1523\/JNEUROSCI.0188-12.2012","article-title":"Hyperdynamic microtubules, cognitive deficits, and pathology are improved in tau transgenic mice with low doses of the microtubule-stabilizing agent BMS-241027","volume":"32","author":"Barten","year":"2012","journal-title":"J. Neurosci."},{"issue":"Suppl 1","key":"10.1016\/j.brainresbull.2019.01.004_bib0075","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/jnc.13425","article-title":"Iron neurochemistry in Alzheimer\u2019s disease and Parkinson\u2019s disease: targets for therapeutics","volume":"139","author":"Belaidi","year":"2016","journal-title":"J. Neurochem."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0080","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00401-009-0522-3","article-title":"Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer\u2019s disease","volume":"118","author":"Bell","year":"2009","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0085","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nn.3028","article-title":"The toxic Abeta oligomer and Alzheimer\u2019s disease: an emperor in need of clothes","volume":"15","author":"Benilova","year":"2012","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0090","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.brainresbull.2017.05.006","article-title":"Cyclin dependent kinase 5: a novel avenue for Alzheimer\u2019s disease","volume":"132","author":"Bhounsule","year":"2017","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0095","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0026860","article-title":"Tau-targeted immunization impedes progression of neurofibrillary histopathology in aged P301L tau transgenic mice","volume":"6","author":"Bi","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0100","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005593","article-title":"Cholinesterase inhibitors for Alzheimer\u2019s disease","author":"Birks","year":"2006","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0105","first-page":"1","article-title":"Alzheimer\u2019s disease\u2013the past, the present and the future","volume":"6","author":"Botchway","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0110","doi-asserted-by":"crossref","first-page":"666","DOI":"10.2174\/156720511796717195","article-title":"Tau as a therapeutic target for Alzheimer\u2019s disease","volume":"8","author":"Boutajangout","year":"2011","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0115","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1212\/01.wnl.0000262031.18018.1a","article-title":"Blood-brain barrier impairment in Alzheimer disease: stability and functional significance","volume":"68","author":"Bowman","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0120","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.bbrc.2016.06.122","article-title":"Structural differences between amyloid beta oligomers","volume":"477","author":"Breydo","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0125","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1093\/brain\/awl269","article-title":"CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer\u2019s disease","volume":"129","author":"Buerger","year":"2006","journal-title":"Brain"},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0130","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.brainresbull.2016.04.019","article-title":"Physiological and pathological roles of the gamma-secretase complex","volume":"126","author":"Carroll","year":"2016","journal-title":"Brain Res. Bull."},{"issue":"Suppl 1","key":"10.1016\/j.brainresbull.2019.01.004_bib0135","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.3233\/JAD-132477","article-title":"Specific targeting of tau oligomers in Htau mice prevents cognitive impairment and tau toxicity following injection with brain-derived tau oligomeric seeds","volume":"40","author":"Castillo-Carranza","year":"2014","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0140","doi-asserted-by":"crossref","first-page":"4260","DOI":"10.1523\/JNEUROSCI.3192-13.2014","article-title":"Passive immunization with Tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles","volume":"34","author":"Castillo-Carranza","year":"2014","journal-title":"J. Neurosci."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0145","doi-asserted-by":"crossref","first-page":"34457","DOI":"10.1074\/jbc.M111.229633","article-title":"Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression","volume":"286","author":"Chai","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0150","doi-asserted-by":"crossref","first-page":"8215","DOI":"10.1073\/pnas.0509725103","article-title":"PKCepsilon increases endothelin converting enzyme activity and reduces amyloid plaque pathology in transgenic mice","volume":"103","author":"Choi","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0155","doi-asserted-by":"crossref","first-page":"29621","DOI":"10.1074\/jbc.R800015200","article-title":"The role of amyloid precursor protein processing by BACE1, the beta-secretase, in Alzheimer disease pathophysiology","volume":"283","author":"Cole","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0062402","article-title":"Tau passive immunotherapy in mutant P301L mice: antibody affinity versus specificity","volume":"8","author":"d\u2019Abramo","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0165","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nn.4188","article-title":"Visualizing APP and BACE-1 approximation in neurons yields insight into the amyloidogenic pathway","volume":"19","author":"Das","year":"2016","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0170","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.neuron.2011.11.033","article-title":"Propagation of tau pathology in a model of early Alzheimer\u2019s disease","volume":"73","author":"de Calignon","year":"2012","journal-title":"Neuron"},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0175","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.bcp.2013.12.012","article-title":"Brain metabolic dysfunction at the core of Alzheimer\u2019s disease","volume":"88","author":"de la Monte","year":"2014","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0180","doi-asserted-by":"crossref","first-page":"24540","DOI":"10.1074\/jbc.M007579200","article-title":"Degradation of the Alzheimer\u2019s amyloid beta peptide by endothelin-converting enzyme","volume":"276","author":"Eckman","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0185","doi-asserted-by":"crossref","first-page":"4565","DOI":"10.1113\/JP270590","article-title":"Membrane lipid rafts and neurobiology: age-related changes in membrane lipids and loss of neuronal function","volume":"594","author":"Egawa","year":"2016","journal-title":"J. Physiol. (Lond.)"},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0190","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.amjmed.2006.08.036","article-title":"Effective pharmacologic management of Alzheimer\u2019s disease","volume":"120","author":"Farlow","year":"2007","journal-title":"Am. J. Med."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0195","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.nlm.2016.09.014","article-title":"Cholinergic neurodegeneration in an Alzheimer mouse model overexpressing amyloid-precursor protein with the Swedish-Dutch-Iowa mutations","volume":"136","author":"Foidl","year":"2016","journal-title":"Neurobiol. Learn. Mem."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0200","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/8501693","article-title":"Current research therapeutic strategies for alzheimer\u2019s disease treatment","volume":"2016","author":"Folch","year":"2016","journal-title":"Neural Plast."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0205","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3233\/JAD-150927","article-title":"Naphthoquinone-tryptophan hybrid inhibits aggregation of the tau-derived peptide PHF6 and reduces neurotoxicity","volume":"51","author":"Frenkel-Pinter","year":"2016","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0210","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1159\/000448518","article-title":"Cl-NQTrp alleviates tauopathy symptoms in a model organism through the inhibition of tau aggregation-engendered toxicity","volume":"17","author":"Frenkel-Pinter","year":"2017","journal-title":"Neurodegener. Dis."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0215","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0019264","article-title":"Beta-carboline compounds, including harmine, inhibit DYRK1A and tau phosphorylation at multiple Alzheimer\u2019s disease-related sites","volume":"6","author":"Frost","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0220","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.it.2008.05.002","article-title":"Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression","volume":"29","author":"Gao","year":"2008","journal-title":"Trends Immunol."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0225","doi-asserted-by":"crossref","first-page":"6765","DOI":"10.1039\/C3CS60460H","article-title":"BACE1 (beta-secretase) inhibitors for the treatment of Alzheimer\u2019s disease","volume":"43","author":"Ghosh","year":"2014","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0230","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1212\/01.WNL.0000063311.58879.01","article-title":"Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer\u2019s disease","volume":"60","author":"Giannakopoulos","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0235","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1212\/01.WNL.0000159740.16984.3C","article-title":"Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial","volume":"64","author":"Gilman","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0240","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.pharep.2015.07.006","article-title":"Therapeutic strategies for Alzheimer\u2019s disease in clinical trials","volume":"68","author":"Godyn","year":"2016","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0245","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/j.1471-4159.2004.02147.x","article-title":"Dephosphorylation of microtubule-associated protein tau by protein phosphatase 5","volume":"88","author":"Gong","year":"2004","journal-title":"J. Neurochem."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0250","doi-asserted-by":"crossref","first-page":"38182","DOI":"10.1074\/jbc.M007489200","article-title":"Structural and functional differences between 3-repeat and 4-repeat tau isoforms. Implications for normal tau function and the onset of neurodegenetative disease","volume":"275","author":"Goode","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0255","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s13073-015-0232-5","article-title":"The age factor in Alzheimer\u2019s disease","volume":"7","author":"Guerreiro","year":"2015","journal-title":"Genome Med."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0260","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrm2101","article-title":"Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer\u2019s amyloid beta-peptide","volume":"8","author":"Haass","year":"2007","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0265","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1126\/science.1072994","article-title":"The amyloid hypothesis of Alzheimer\u2019s disease: progress and problems on the road to therapeutics","volume":"297","author":"Hardy","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0270","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S1474-4422(15)70016-5","article-title":"Neuroinflammation in Alzheimer\u2019s disease","volume":"14","author":"Heneka","year":"2015","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0275","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/jnc.12845","article-title":"Clearing the way for tau immunotherapy in Alzheimer\u2019s disease","volume":"132","author":"Herrmann","year":"2015","journal-title":"J. Neurochem."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0280","doi-asserted-by":"crossref","first-page":"25326","DOI":"10.1074\/jbc.272.40.25326","article-title":"Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3","volume":"272","author":"Hong","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0285","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0166-2236(00)02004-X","article-title":"Molecular physiology and pathophysiology of tight junctions in the blood-brain barrier","volume":"24","author":"Huber","year":"2001","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0290","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/ana.1061","article-title":"Autoantibodies to amyloid-beta and Alzheimer\u2019s disease","volume":"49","author":"Hyman","year":"2001","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0295","doi-asserted-by":"crossref","first-page":"7751","DOI":"10.1074\/jbc.C200711200","article-title":"The Notch ligands, Delta1 and Jagged2, are substrates for presenilin-dependent \u201c\u03b3-secretase\u201d cleavage","volume":"278","author":"Ikeuchi","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0300","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.bbadis.2004.09.008","article-title":"Tau pathology in Alzheimer disease and other tauopathies","volume":"1739","author":"Iqbal","year":"2005","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0305","doi-asserted-by":"crossref","first-page":"656","DOI":"10.2174\/156720510793611592","article-title":"Tau in Alzheimer disease and related tauopathies","volume":"7","author":"Iqbal","year":"2010","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0310","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.cmet.2015.08.016","article-title":"Metabolic and non-cognitive manifestations of alzheimer\u2019s disease: the hypothalamus as both culprit and target of pathology","volume":"22","author":"Ishii","year":"2015","journal-title":"Cell Metab."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0315","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0010549","article-title":"Antibodies targeted to the brain with image-guided focused ultrasound reduces amyloid-beta plaque load in the TgCRND8 mouse model of Alzheimer\u2019s disease","volume":"5","author":"Jordao","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0320","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.tips.2015.01.005","article-title":"The 12\/15-lipoxygenase as an emerging therapeutic target for Alzheimer\u2019s disease","volume":"36","author":"Joshi","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0325","doi-asserted-by":"crossref","first-page":"7501","DOI":"10.1073\/pnas.1504081112","article-title":"Tau stabilizes microtubules by binding at the interface between tubulin heterodimers","volume":"112","author":"Kadavath","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0330","first-page":"27","article-title":"Alzheimer\u2019s disease and immunotherapy: what is wrong with clinical trials?","volume":"4","author":"Kohyama","year":"2015","journal-title":"Immunotargets Ther."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0335","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.neuron.2010.08.018","article-title":"Modulation of gamma-secretase reduces beta-amyloid deposition in a transgenic mouse model of Alzheimer\u2019s disease","volume":"67","author":"Kounnas","year":"2010","journal-title":"Neuron"},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0340","first-page":"65","article-title":"NGP 555, a gamma-secretase modulator, lowers the amyloid biomarker, Abeta42, in cerebrospinal fluid while preventing alzheimer\u2019s disease cognitive decline in rodents","volume":"3","author":"Kounnas","year":"2017","journal-title":"Alzheimer\u2019s Dementia"},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0345","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.tips.2017.10.008","article-title":"Insulin-degrading enzyme in the fight against alzheimer\u2019s disease","volume":"39","author":"Kurochkin","year":"2018","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0350","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/joim.12168","article-title":"Amyloid-ss-directed immunotherapy for Alzheimer\u2019s disease","volume":"275","author":"Lannfelt","year":"2014","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0355","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1093\/embo-reports\/kvd107","article-title":"Brain plasmin enhances APP alpha-cleavage and Abeta degradation and is reduced in Alzheimer\u2019s disease brains","volume":"1","author":"Ledesma","year":"2000","journal-title":"EMBO Rep."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0360","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1038\/sj.embor.7400021","article-title":"Raft disorganization leads to reduced plasmin activity in Alzheimer\u2019s disease brains","volume":"4","author":"Ledesma","year":"2003","journal-title":"EMBO Rep."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0365","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/ana.20592","article-title":"Abeta42 immunization in Alzheimer\u2019s disease generates Abeta N-terminal antibodies","volume":"58","author":"Lee","year":"2005","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0370","doi-asserted-by":"crossref","first-page":"4292","DOI":"10.1074\/jbc.M511018200","article-title":"Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice","volume":"281","author":"Lee","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0375","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nrneurol.2009.219","article-title":"Can Alzheimer disease be prevented by amyloid-beta immunotherapy?","volume":"6","author":"Lemere","year":"2010","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0380","article-title":"Trans-synaptic spread of tau pathology in vivo","volume":"7","author":"Liu","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0385","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.neuropharm.2014.11.018","article-title":"Role of the nicotinic acetylcholine receptor in Alzheimer\u2019s disease pathology and treatment","volume":"96","author":"Lombardo","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0390","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1124\/jpet.107.130526","article-title":"A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer\u2019s disease","volume":"325","author":"Matsuoka","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0395","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0143-4160(03)00128-3","article-title":"Neuronal and glial calcium signaling in Alzheimer\u2019s disease","volume":"34","author":"Mattson","year":"2003","journal-title":"Cell Calcium"},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0400","doi-asserted-by":"crossref","first-page":"38992","DOI":"10.1074\/jbc.M112.348037","article-title":"A novel inhibitor of amyloid beta (Abeta) peptide aggregation: from high throughput screening to efficacy in an animal model of Alzheimer disease","volume":"287","author":"McKoy","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0405","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1038\/nm790","article-title":"Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis","volume":"8","author":"McLaurin","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0410","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.bcp.2014.01.013","article-title":"New perspectives on the role of tau in Alzheimer\u2019s disease. Implications for therapy","volume":"88","author":"Medina","year":"2014","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0415","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.mcn.2012.02.005","article-title":"Estrogen activates matrix metalloproteinases-2 and -9 to increase beta amyloid degradation","volume":"49","author":"Merlo","year":"2012","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0420","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1742-4933-10-18","article-title":"Passive anti-amyloid immunotherapy in Alzheimer\u2019s disease: What are the most promising targets?","volume":"10","author":"Moreth","year":"2013","journal-title":"Immun. Ageing"},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0425","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1365-2796.2010.02315.x","article-title":"Immunotherapy for Alzheimer\u2019s disease","volume":"269","author":"Morgan","year":"2011","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0430","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/sj.mp.4001483","article-title":"GSK-3beta inhibition reverses axonal transport defects and behavioural phenotypes in Drosophila","volume":"9","author":"Mudher","year":"2004","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0435","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a006288","article-title":"Physiological functions of APP family proteins","volume":"2","author":"Muller","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0440","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2174\/1874070701105010039","article-title":"Short peptides as inhibitors of amyloid aggregation","volume":"5","author":"Neddenriep","year":"2011","journal-title":"Open Biotechnol. J."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0445","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/bpa.12368","article-title":"Targeted antioxidant, Catalase-SKL, reduces beta-amyloid toxicity in the rat brain","volume":"27","author":"Nell","year":"2017","journal-title":"Brain Pathol."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0450","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0896-6273(03)00434-3","article-title":"Triple-transgenic model of Alzheimer\u2019s disease with plaques and tangles: intracellular Abeta and synaptic dysfunction","volume":"39","author":"Oddo","year":"2003","journal-title":"Neuron"},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0455","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nbd.2018.01.015","article-title":"Prion-like seeding and nucleation of intracellular amyloid-beta","volume":"113","author":"Olsson","year":"2018","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0460","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3233\/JAD-2004-6107","article-title":"The role of the endosomal\/lysosomal system in amyloid-beta production and the pathophysiology of Alzheimer\u2019s disease: reexamining the spatial paradox from a lysosomal perspective","volume":"6","author":"Pasternak","year":"2004","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0465","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1074\/jbc.M410984200","article-title":"Anthraquinones inhibit tau aggregation and dissolve Alzheimer\u2019s paired helical filaments in vitro and in cells","volume":"280","author":"Pickhardt","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0470","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/j.1471-4159.2007.04591.x","article-title":"In vivo targeting of antibody fragments to the nervous system for Alzheimer\u2019s disease immunotherapy and molecular imaging of amyloid plaques","volume":"102","author":"Poduslo","year":"2007","journal-title":"J. Neurochem."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0475","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1091\/mbc.E17-06-0429","article-title":"Tau can switch microtubule network organizations: from random networks to dynamic and stable bundles","volume":"29","author":"Prezel","year":"2018","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0480","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jalz.2012.11.007","article-title":"The global prevalence of dementia: a systematic review and metaanalysis","volume":"9","author":"Prince","year":"2013","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0485","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ebiom.2017.08.028","article-title":"Soluble gamma-secretase modulators attenuate alzheimer\u2019s beta-amyloid pathology and induce conformational changes in presenilin 1","volume":"24","author":"Raven","year":"2017","journal-title":"EBioMedicine"},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0490","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.nbd.2017.06.005","article-title":"Novel human neuronal tau model exhibiting neurofibrillary tangles and transcellular propagation","volume":"106","author":"Reilly","year":"2017","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0495","doi-asserted-by":"crossref","first-page":"6635","DOI":"10.2174\/13816128113199990613","article-title":"Targeted drug delivery across the blood brain barrier in Alzheimer\u2019s disease","volume":"19","author":"Rocha","year":"2013","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0500","doi-asserted-by":"crossref","first-page":"41051","DOI":"10.1038\/srep41051","article-title":"Evidence for intramolecular antiparallel beta-sheet structure in Alpha-Synuclein fibrils from a combination of two-dimensional infrared spectroscopy and atomic force microscopy","volume":"7","author":"Roeters","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0505","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.cell.2016.05.020","article-title":"Restricted location of PSEN2\/gamma-Secretase determines substrate specificity and generates an intracellular abeta pool","volume":"166","author":"Sannerud","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0510","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.brainres.2016.05.026","article-title":"Expression of microRNA-34a in Alzheimer\u2019s disease brain targets genes linked to synaptic plasticity, energy metabolism, and resting state network activity","volume":"1646","author":"Sarkar","year":"2016","journal-title":"Brain Res."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0515","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.neuropharm.2015.12.006","article-title":"BIIB042, a novel gamma-secretase modulator, reduces amyloidogenic Abeta isoforms in primates and rodents and plaque pathology in a mouse model of Alzheimer\u2019s disease","volume":"103","author":"Scannevin","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0520","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1735338100","article-title":") A presenilin dimer at the core of the \u03b3-secretase enzyme: insights from parallel analysis of Notch 1 and APP proteolysis","volume":"100","author":"Schroeter","year":"2003","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0525","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.brainresbull.2017.03.010","article-title":"Long non-coding RNAs in brain development, synaptic biology, and Alzheimer\u2019s disease","volume":"132","author":"Shi","year":"2017","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0530","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ynstr.2018.08.009","article-title":"Tauopathy and neurodegeneration: a role for stress","volume":"9","author":"Sierra-Fonseca","year":"2018","journal-title":"Neurobiol. Stress"},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0535","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.neuroscience.2004.08.028","article-title":"Gamma-secretase subunit composition and distribution in the presenilin wild-type and mutant mouse brain","volume":"129","author":"Siman","year":"2004","journal-title":"Neuroscience"},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0540","doi-asserted-by":"crossref","first-page":"7638","DOI":"10.1073\/pnas.1230693100","article-title":"The Notch ligand Delta1 is sequentially cleaved by an ADAM protease and \u03b3-secretase","volume":"100","author":"Six","year":"2003","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0545","doi-asserted-by":"crossref","first-page":"30670","DOI":"10.1074\/jbc.M115.691493","article-title":"The voltage-dependent anion channel 1 mediates amyloid beta toxicity and represents a potential target for alzheimer disease therapy","volume":"290","author":"Smilansky","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0550","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0105383","article-title":"Integrating transcriptomics with metabolic modeling predicts biomarkers and drug targets for Alzheimer\u2019s disease","volume":"9","author":"Stempler","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0555","doi-asserted-by":"crossref","first-page":"11612","DOI":"10.1074\/jbc.M210207200","article-title":"In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis","volume":"278","author":"Stine","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0560","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1742-2094-1-14","article-title":"Microglia and neuroinflammation: a pathological perspective","volume":"1","author":"Streit","year":"2004","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0565","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/febs.13103","article-title":"Combining an amyloid-beta (Abeta) cleaving enzyme inhibitor with a gamma-secretase modulator results in an additive reduction of Abeta production","volume":"282","author":"Stromberg","year":"2015","journal-title":"FEBS J."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0570","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/j.1471-4159.2007.04742.x","article-title":"A role for 12\/15 lipoxygenase in the amyloid beta precursor protein metabolism","volume":"103","author":"Succol","year":"2007","journal-title":"J. Neurochem."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0575","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/dneu.22556","article-title":"The physical approximation of APP and BACE-1: a key event in alzheimer\u2019s disease pathogenesis","volume":"78","author":"Sun","year":"2018","journal-title":"Dev. Neurobiol."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0580","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nrneurol.2015.119","article-title":"Clearance systems in the brain-implications for Alzheimer disease","volume":"11","author":"Tarasoff-Conway","year":"2015","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0585","doi-asserted-by":"crossref","first-page":"29615","DOI":"10.1074\/jbc.R800019200","article-title":"Amyloid precursor protein trafficking, processing, and function","volume":"283","author":"Thinakaran","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0590","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.brainresbull.2016.06.005","article-title":"Oxidative stress, protein modification and Alzheimer disease","volume":"133","author":"Tramutola","year":"2017","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0595","doi-asserted-by":"crossref","first-page":"397","DOI":"10.2174\/156720512800492503","article-title":"Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach","volume":"9","author":"Troquier","year":"2012","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0600","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.biopsych.2017.08.010","article-title":"Anti-amyloid-beta monoclonal antibodies for alzheimer\u2019s disease: pitfalls and promise","volume":"83","author":"van Dyck","year":"2018","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0605","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.neulet.2014.05.047","article-title":"p-Tau immunotherapy reduces soluble and insoluble tau in aged 3xTg-AD mice","volume":"575","author":"Walls","year":"2014","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0610","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.brainresbull.2016.08.002","article-title":"O-GlcNAcylation and neurodegeneration","volume":"133","author":"Wani","year":"2017","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0615","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1111\/jnc.13866","article-title":"Formation, release, and internalization of stable tau oligomers in cells","volume":"139","author":"Wegmann","year":"2016","journal-title":"J. Neurochem."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0620","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/1531-8249(200010)48:4<567::AID-ANA3>3.0.CO;2-W","article-title":"Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer\u2019s disease","volume":"48","author":"Weiner","year":"2000","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0625","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.brainresbull.2016.08.009","article-title":"Amyloid precursor protein processing and bioenergetics","volume":"133","author":"Wilkins","year":"2017","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0630","doi-asserted-by":"crossref","first-page":"11213","DOI":"10.1073\/pnas.93.20.11213","article-title":"Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines","volume":"93","author":"Wischik","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0635","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.bcp.2013.12.008","article-title":"Tau-aggregation inhibitor therapy for Alzheimer\u2019s disease","volume":"88","author":"Wischik","year":"2014","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0640","doi-asserted-by":"crossref","DOI":"10.1016\/j.jalz.2016.06.2161","article-title":"The amyloid-B generating TRI-PEPTIDE cleavage mechanism of gamma-secretase: implications for Alzheimer\u2019s disease","volume":"12","author":"Wolfe","year":"2016","journal-title":"Alzheimer\u2019s Dementia"},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0645","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00401-015-1477-1","article-title":"Physiological amyloid-beta clearance in the periphery and its therapeutic potential for Alzheimer\u2019s disease","volume":"130","author":"Xiang","year":"2015","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0650","doi-asserted-by":"crossref","first-page":"24566","DOI":"10.1074\/jbc.M602440200","article-title":"Matrix metalloproteinase-9 degrades amyloid-beta fibrils in vitro and compact plaques in situ","volume":"281","author":"Yan","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0655","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/1756285612461679","article-title":"Current and future treatments for Alzheimer\u2019s disease","volume":"6","author":"Yiannopoulou","year":"2013","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0660","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/PL00007428","article-title":"Selective distribution of matrix metalloproteinase-3 (MMP-3) in Alzheimer\u2019s disease brain","volume":"99","author":"Yoshiyama","year":"2000","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.brainresbull.2019.01.004_bib0665","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1750-1326-6-27","article-title":"Biology and pathophysiology of the amyloid precursor protein","volume":"6","author":"Zheng","year":"2011","journal-title":"Mol. Neurodegener."}],"container-title":["Brain Research Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0361923018308499?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0361923018308499?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T20:34:32Z","timestamp":1759782872000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0361923018308499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":133,"alternative-id":["S0361923018308499"],"URL":"https:\/\/doi.org\/10.1016\/j.brainresbull.2019.01.004","relation":{},"ISSN":["0361-9230"],"issn-type":[{"value":"0361-9230","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent therapeutic strategies targeting beta amyloid and tauopathies in Alzheimer's disease","name":"articletitle","label":"Article Title"},{"value":"Brain Research Bulletin","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.brainresbull.2019.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}